1. Home
  2. DVA vs CORT Comparison

DVA vs CORT Comparison

Compare DVA & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$115.50

Market Cap

8.4B

Sector

Health Care

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

HOLD

Current Price

$82.37

Market Cap

8.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DVA
CORT
Founded
1994
1998
Country
United States
United States
Employees
N/A
500
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4B
8.6B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
DVA
CORT
Price
$115.50
$82.37
Analyst Decision
Hold
Buy
Analyst Count
4
6
Target Price
$145.00
$130.20
AVG Volume (30 Days)
975.3K
890.8K
Earning Date
10-29-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
5.63
N/A
EPS
9.76
0.87
Revenue
$13,317,965,000.00
$741,172,000.00
Revenue This Year
$6.50
$23.79
Revenue Next Year
$2.97
$40.97
P/E Ratio
$11.89
$93.35
Revenue Growth
5.14
17.92
52 Week Low
$113.97
$49.00
52 Week High
$179.60
$117.33

Technical Indicators

Market Signals
Indicator
DVA
CORT
Relative Strength Index (RSI) 38.88 51.93
Support Level $115.91 $78.07
Resistance Level $122.40 $83.37
Average True Range (ATR) 2.52 3.39
MACD -0.02 -0.43
Stochastic Oscillator 7.76 38.06

Price Performance

Historical Comparison
DVA
CORT

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Share on Social Networks: